Kalytera Announces Change of Auditor
August 31, 2020 13:26 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that Kost Forer Gabbay &...
Kalytera Announces Closing of Private Placement of Common Shares and Common Share Purchase Warrants, and Provides Corporate Update
August 07, 2020 18:29 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today provided the following updates regarding recent and...
Kalytera Announces Escrowed Closing of Private Placement of Common Shares and Common Share Purchase Warrants
July 24, 2020 13:11 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, July 24, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that on and effective July 22, 2020 it...
Kalytera Announces Exclusive License Agreement with Salzman Group for Development and Commercialization of R-107 for Treatment of Coronavirus and COVID-19 Infection
July 16, 2020 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, July 16, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that it has entered into a License...
Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants
July 15, 2020 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, July 15, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announces that it has received conditional approval from...
Kalytera Provides Updates Regarding Annual Filings, the Acquisition of Salzman Group, and the Company’s Private Placement
June 30, 2020 14:22 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, June 30, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today provided updates regarding the following three...
Kalytera Provides Update Regarding Acquisition of Salzman Group
June 16, 2020 07:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, June 16, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") announced today that it is working with Salzman Group...
Kalytera Announces Data Demonstrating that R-107 Prevents Tissue Damage and Increases Survival in a Murine Study of Chlorine Inhalational Lung Injury
June 15, 2020 07:30 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, June 15, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced proof-of-concept data demonstrating that...
Kalytera Announces Updates to Its Annual and Interim Filings
June 11, 2020 07:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, June 11, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") is providing an update to its news release dated April...
Kalytera Announces Data from Study in Rats Demonstrating Proof of Concept for R-107 in COVID-19 Associated PAH
June 09, 2020 07:00 ET
|
Kalytera Therapeutics Inc.
SAN FRANCISCO, June 09, 2020 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced new proof-of-concept data for R-107, its...